Celon Pharma on the development of cancer drugs at the ORTC-NCI-AACR SYMPOSIUM

Aleksandra Stańczak, PhD, Leader of the Oncology Research Group will present results for two inhibitors under Celon Pharma’s development at the 30th symposium organised by European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and  American Association for Cancer Research (AACR), to be held on 13-16. November in Dublin.

The following projects will be presented in the poster session:

1. CPL-410-005, a novel ubiquitin-activating enzyme (UAE) inhibitor in preclinical evaluation as an anticancer treatment for solid tumors.
2. Rational-based drug design of novel, highly potent MER inhibitors as potential treatment of cancers.

The latest reports on the development of cancer drugs will be presented at the Symposium. The meeting will be participated by scientists and representatives of the pharmaceutical sector from around the world.